Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data

TY - JOUR

T1 - Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data

AU - Coward, Stephanie

AU - Clement, Fiona

AU - Benchimol, Eric I.

AU - Bernstein, Charles N.

AU - Avina-Zubieta, J. Antonio

AU - Bitton, Alain

AU - Carroll, Mathew W.

AU - Hazlewood, Glen

AU - Jacobson, Kevan

AU - Jelinski, Susan

AU - Deardon, Rob

AU - Jones, Jennifer L.

AU - Kuenzig, M. Ellen

AU - Leddin, Desmond

AU - McBrien, Kerry A.

AU - Murthy, Sanjay K.

AU - Nguyen, Geoffrey C.

AU - Otley, Anthony R.

AU - Panaccione, Remo

AU - Rezaie, Ali

AU - Rosenfeld, Greg

AU - Peña-Sánchez, Juan Nicolás

AU - Singh, Harminder

AU - Targownik, Laura E.

AU - Kaplan, Gilaad G.

N1 - Funding Information: Disclaimer: This study is based in part on de-identified data provided by Alberta Health Services, Régie de l’assurance maladie du Québec, Ministry of Health of British Columbia and Population Data BC, Saskatchewan Ministry of Health, Health Data Nova Scotia of Dalhousie University, and Manitoba Health. The interpretation and conclusions contained herein are those of the researchers and do not necessarily represent the views of the Government of Alberta, Government of Quebec, Government of British Columbia, Government of Saskatchewan or the Ministry of Health, Health Data Nova Scotia or the Department of Health and Wellness, or the Government of Manitoba. Neither the Government of Alberta nor Alberta Health Services expressed any opinion in relation to this study. This study was supported by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by Institute for Clinical Evaluative Sciences or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred. The interpretation and conclusions contained herein do not necessarily represent those of the Government of Saskatchewan or the Ministry of Health. Although this research and health service assessment analysis is based on data obtained from the Nova Scotia Department of Health and Wellness, the observations and opinions expressed are those of the authors and do not represent those of Health Data Nova Scotia or the Department of Health and Wellness. Funding Information: Funding This study was supported by a CIHR Project Grant (funding reference number 153420) and a CIHR Team Grant (Health Challenges in Chronic Inflammation, grant THC-135235). The project was supported by the Digestive Health Strategic Clinical Network, Alberta Health Services. Gilaad G. Kaplan is a CIHR Embedded Clinician Research Chair. Stephanie Coward is supported by an Izaak Walton Killam Doctoral Scholarship and an Eyes High Doctoral Recruitment Scholarship. Eric I. Benchimol is supported by a New Investigator Award from CIHR, Crohn's and Colitis Canada, and the Canadian Association of Gastroenterology. Eric I. Benchimol also is supported by the Career Enhancement Program of the Canadian Child Health Clinician Scientist Program. Charles N. Bernstein is supported in part by the Bingham Chair in Gastroenterology. M. Ellen Kuenzig is supported by a CIHR Postdoctoral Fellowship. Conflicts of interest Charles N. Bernstein been on the advisory boards for AbbVie Canada, Ferring Canada, Janssen Canada, Shire Canada, Takeda Canada, Pfizer Canada, and Napo Pharmaceuticals; consulted to 4D Pharma and Mylan Pharmaceuticals; has received educational grants from AbbVie Canada, Pfizer Canada, Shire Canada, Takeda Canada, Janssen Canada; and has been on the speaker's panel for Ferring Canada, Medtronic Canada, and Shire Canada. Harminder Singh is on an advisory board for Merck Canada, Ferring Canada and has a research grant from Merck Canada. Laura E. Targownik is on the advisory board for Takeda, Janssen, AbbVie, Merck, Pfizer, and Ferring; received research funds from Janssen; and is a speaker for Takeda, Janssen, and AbbVie. Gilaad G. Kaplan has served as a speaker for Janssen, AbbVie, and Pfizer and has received research support from Janssen, AbbVie, GlaxoSmithKline, and Shire. Stephanie Coward, Alain Bitton, Anthony R. Otley, Ali Rezaie, Des Leddin, Eric I. Benchimol, Fiona Clement, Glen Hazlewood, Geoffrey C. Nguyen, Greg Rosenfeld, J. Antonio Avina-Zubieta, Jennifer L. Jones, Juan Nicolás Peña-Sánchez, Kerry A. McBrien, Kevan Jacobson, Mathew W. Carroll, M. Ellen Kuenzig, Remo Panaccione, Rob Deardon, Susan Jelinski, and Sanjay K. Murthy have no conflicts of interest to declare. Funding This study was supported by a CIHR Project Grant (funding reference number 153420) and a CIHR Team Grant (Health Challenges in Chronic Inflammation, grant THC-135235). The project was supported by the Digestive Health Strategic Clinical Network, Alberta Health Services. Gilaad G. Kaplan is a CIHR Embedded Clinician Research Chair. Stephanie Coward is supported by an Izaak Walton Killam Doctoral Scholarship and an Eyes High Doctoral Recruitment Scholarship. Eric I. Benchimol is supported by a New Investigator Award from CIHR, Crohn's and Colitis Canada, and the Canadian Association of Gastroenterology. Eric I. Benchimol also is supported by the Career Enhancement Program of the Canadian Child Health Clinician Scientist Program. Charles N. Bernstein is supported in part by the Bingham Chair in Gastroenterology. M. Ellen Kuenzig is supported by a CIHR Postdoctoral Fellowship. Disclaimer: This study is based in part on de-identified data provided by Alberta Health Services, Régie de l'assurance maladie du Québec, Ministry of Health of British Columbia and Population Data BC, Saskatchewan Ministry of Health, Health Data Nova Scotia of Dalhousie University, and Manitoba Health. The interpretation and conclusions contained herein are those of the researchers and do not necessarily represent the views of the Government of Alberta, Government of Quebec, Government of British Columbia, Government of Saskatchewan or the Ministry of Health, Health Data Nova Scotia or the Department of Health and Wellness, or the Government of Manitoba. Neither the Government of Alberta nor Alberta Health Services expressed any opinion in relation to this study. This study was supported by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by Institute for Clinical Evaluative Sciences or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred. The interpretation and conclusions contained herein do not necessarily represent those of the Government of Saskatchewan or the Ministry of Health. Although this research and health service assessment analysis is based on data obtained from the Nova Scotia Department of Health and Wellness, the observations and opinions expressed are those of the authors and do not represent those of Health Data Nova Scotia or the Department of Health and Wellness. An interactive web-based map describing the prevalence of IBD across Canada from 2002 to 2030 is available at this link https://people.ucalgary.ca/∼ggkaplan/IBDCPREV.html, Author contributions: Stephanie Coward contributed to study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; and statistical analysis. Fiona Clement, Charles N. Bernstein, Mathew W. Carroll, Glen Hazlewood, Kevan Jacobson, M. Ellen Kuenzig, Des Leddin, Kerry A. McBrien, Sanjay K. Murthy, Remo Panaccione, Ali Rezaie, and Harminder Singh contributed to study design and critical revision of the manuscript for important intellectual content. Eric I. Benchimol, J. Antonio Avina-Zubieta, Alain Bitton, Susan Jelinski, Jennifer L. Jones, Geoffrey C. Nguyen, Anthony R. Otley, Greg Rosenfeld, Juan Nicolás Peña-Sánchez, and Laura E. Targownik contributed to study design, data acquisition, critical revision of the manuscript for important intellectual content, and obtained funding. Rob Deardon and Ali Rezaie contributed to study design, interpretation of data, and critical revision of the manuscript for important intellectual content. Gilaad G. Kaplan contributed to study concept and design; acquisition of data; interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; obtained funding; administrative, technical, or material support; and study supervision. Conflicts of interest Charles N. Bernstein been on the advisory boards for AbbVie Canada, Ferring Canada, Janssen Canada, Shire Canada, Takeda Canada, Pfizer Canada, and Napo Pharmaceuticals; consulted to 4D Pharma and Mylan Pharmaceuticals; has received educational grants from AbbVie Canada, Pfizer Canada, Shire Canada, Takeda Canada, Janssen Canada; and has been on the speaker's panel for Ferring Canada, Medtronic Canada, and Shire Canada. Harminder Singh is on an advisory board for Merck Canada, Ferring Canada and has a research grant from Merck Canada. Laura E. Targownik is on the advisory board for Takeda, Janssen, AbbVie, Merck, Pfizer, and Ferring; received research funds from Janssen; and is a speaker for Takeda, Janssen, and AbbVie. Gilaad G. Kaplan has served as a speaker for Janssen, AbbVie, and Pfizer and has received research support from Janssen, AbbVie, GlaxoSmithKline, and Shire. Stephanie Coward, Alain Bitton, Anthony R. Otley, Ali Rezaie, Des Leddin, Eric I. Benchimol, Fiona Clement, Glen Hazlewood, Geoffrey C. Nguyen, Greg Rosenfeld, J. Antonio Avina-Zubieta, Jennifer L. Jones, Juan Nicolás Peña-Sánchez, Kerry A. McBrien, Kevan Jacobson, Mathew W. Carroll, M. Ellen Kuenzig, Remo Panaccione, Rob Deardon, Susan Jelinski, and Sanjay K. Murthy have no conflicts of interest to declare. Funding This study was supported by a CIHR Project Grant (funding reference number 153420) and a CIHR Team Grant (Health Challenges in Chronic Inflammation, grant THC-135235). The project was supported by the Digestive Health Strategic Clinical Network, Alberta Health Services. Gilaad G. Kaplan is a CIHR Embedded Clinician Research Chair. Stephanie Coward is supported by an Izaak Walton Killam Doctoral Scholarship and an Eyes High Doctoral Recruitment Scholarship. Eric I. Benchimol is supported by a New Investigator Award from CIHR, Crohn's and Colitis Canada, and the Canadian Association of Gastroenterology. Eric I. Benchimol also is supported by the Career Enhancement Program of the Canadian Child Health Clinician Scientist Program. Charles N. Bernstein is supported in part by the Bingham Chair in Gastroenterology. M. Ellen Kuenzig is supported by a CIHR Postdoctoral Fellowship. Publisher Copyright: © 2019 AGA Institute

PY - 2019/4

Y1 - 2019/4

UR - http://www.scopus.com/inward/record.url?scp=85063385512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063385512&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2019.01.002

DO - 10.1053/j.gastro.2019.01.002

M3 - Article

C2 - 30639677

AN - SCOPUS:85063385512

SN - 0016-5085

VL - 156

SP - 1345-1353.e4

JO - Gastroenterology

JF - Gastroenterology

IS - 5

ER -